Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for May 2011
May 2, 2011
- Treatment with NanoViricides FluCide Drug Candidates Resulted in a 1000-fold Reduction of Viral Load in the Lungs of Animals Infected with Lethal Dose of Influenza Virus
- Concert Pharmaceuticals Presents Preclinical Data on Novel Deuterium-Containing Drug Compound at Antiepileptic Drug Trials XI Conference
- Cubist Pharmaceuticals' Antibiotic Programs Featured in 18 Abstracts at 21st ECCMID/27th ICC Joint Congress
- Xenon's XEN402 ointment significantly relieves pain in patients with post herpetic neuralgia
- Esperion Announces Results From Phase 1 Study and Four Preclinical Studies for ETC-1002
- Study Finds Desirudin Superior to Enoxaparin in Patients with Poor Kidney Function Undergoing Orthopedic Surgery
- Affinium Pharmaceuticals, Ltd., Announces Results of AFN-1252 Multiple Ascending Dose Phase I Clinical Trial
- Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
- Merck: Phase III Data for Investigational Glaucoma Treatment Tafluprost Presented at ARVO
May 3, 2011
- QLT Announces Positive Results from Phase 1b Trial of QLT091001 in Subjects With Leber Congenital Amaurosis
- Discovery Labs' Aerosolized KL4 Surfactant Significantly Improves Lung Function and Survival in Established Model of Acute Lung Injury
- Rib-X Pharmaceuticals to Present Six Abstracts at 21st Annual ECCMID/ 27th Annual ICC Conference
- pSivida Announces New Safety and Efficacy Data from Phase 3 Study of ILUVIEN in Diabetic Macular Edema
- FibroGen Reports Proof-of-Principle for Oral Anemia Therapy FG-4592 in Hemodialysis Patients Switched from Intravenous rhEPO in an Active-Controlled Randomized Phase 2 Study
- PRISTIQ (desvenlafaxine) Extended Release Tablets Shown To Significantly Reduce Number And Severity Of Moderate-To-Severe Hot Flashes Associated With Menopause
- Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes
- Earlier Memory Loss Tied to Cardiovascular Risks & Alzheimer's Gene
- MedImmune to Present Eleven Abstracts on Influenza and Respiratory Syncytial Virus at the Annual Pediatric Academic Societies Meeting
May 4, 2011
- Positive phase 2a results of Akebia's AKB-6548 for anemia
- Accentia Biopharmaceuticals Announces that Revimmune Autoimmune Disease Therapy is Featured in Peer-review Journal
- Ironwood and Forest to Present Linaclotide Results from Phase 3 Trials in Patients with Irritable Bowel Syndrome with Constipation
- Discovery Labs' Aerosolized KL4 Surfactant Program Data Presented at the Pediatric Academic Societies Annual Meeting
- Retrospective Analysis Explores LYSTEDA's Ability to Reduce Sleep Interruptions in Women With Cyclic Heavy Menstrual Bleeding
- Plato BioPharma Presenting Poster at the American Thoracic Society Conference
- Promedior Announces Presentation of Preclinical Data at ARVO Demonstrating PRM-151 (rhPTX-2) Reduces Neovascularization in Retinal Diseases
- A Little Belly Fat Can Double the Risk of Death in Coronary Artery Disease Patients
May 5, 2011
- Promedior to Present Clinical Data for PRM-151 (rhPTX-2) in Idiopathic Pulmonary Fibrosis at ATS 2011
- PolyMedix Announces Presentation of Four Abstracts at ECCMID 2011 Meeting
- Omeros Announces Expansion of Potential Indications for PDE7 Inhibitors
- New Analysis Representing Largest Available Dataset Highlights Relative Safety of Lucentis (Ranibizumab) Compared to Unlicensed Intravitreal Avastin (Bevacizumab)
- Santhera Presents Positive Data from IONIA Open-Label Extension Study in Friedreich's Ataxia at the Fourth International Friedreich's Ataxia Scientific Conference
- ImmunoCellular Therapeutics Announces Updated Long-Term Disease-Free Survival Data from Phase I Study in Glioblastoma
- Millennium Leadership in Proteasome Inhibition Highlighted in Relapsed/Refractory Multiple Myeloma At IMW Meeting
- Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
- Article in Current Opinion in Immunology Journal Declares Coming "Decade of DNA Vaccines"
- Santarus Announces Oral Presentations of Budesonide MMX Phase III Data at Digestive Disease Week Meeting
- Aradigm to Present Additional ORBIT-2 Clinical Trial Results at Respiratory Drug Delivery Europe 2011 Conference
- PolyMedix Presents Data on PMX-60056 at the American Heart Association ATVB-2011 Meeting
- The International Myeloma Foundation: Study Says Long-Term Maintenance Treatment Demonstrates 90% Overall Survival Rate
- Cempra Pharmaceuticals to Present Data on Solithromycin (CEM-101) and TAKSTA (CEM-102) at the 21st European Congress of Clinical Microbiology and Infectious Disease (ECCMID)/27th International Congress of Chemotherapy (ICC)
- Lymphoseek (Tilmanocept) Meets All Endpoints in NEO3-09 Phase 3 Study
May 6, 2011
- VELCADE Improved Outcomes in Multiple Myeloma Patients After Transplant in Nordic Myeloma Study
- Neoprobe's Lymphoseek Met All Endpoints in the Phase III NEO3-09 Study- NDA Submission Expected 3Q11
- Cephalon Presents Positive Results with NUVIGIL in Largest Shift Work Disorder Trial Ever Conducted
- Drinking Coffee, Having Sex Are Triggers That Raise Rupture Risks for Brain Aneurysm
- Depomed's Gralise Shown To Have Similar Efficacy and Adverse Event Profiles in Patients At Least 65 Years Old Compared With Patients Overall
- Argos Therapeutics' Immunotherapy Platform Based on Recombinant Human Soluble CD83 Demonstrates Significant Promise For Solid Organ Transplantation
- ?Bad? Cholesterol Not As Bad As People Think, Shows Texas A&M Study
May 9, 2011
- Staphylococcus aureus Investigational Vaccine Elicits a Positive Immune Response in Phase 1 Study
- Durata Announces Supportive Data Analysis from Phase 3 Dalbavancin Trial at ECCMID Meeting
- New Data Reinforces Gardasil's Safety Profile
- 4SC's Vidofludimus Inhibits IL-17 Production by Interference With the JAK/STAT and NF-ï?«B Pathways
- Tetraphase Presents Data Demonstrating Robust Activity and Dosing Flexibility of Intravenous and Oral Next-Generation Antibiotic Candidates Targeting Complicated, Multidrug-Resistant Pathogens
- Inovio Reports Long-Term Immune Responses from Cervical Dysplasia
- Santhera Presents Data from 2-Year Open-Label Intervention Study with Catena in Duchenne Muscular Dystrophy at the MYOLOGY 2011 Conference
- Pfizer's Prevnar 13 Meets All Study Endpoints In Two Pivotal Phase 3 Trials In Adults Aged 50 And Older Presented Today
- Basilea's antibiotic BAL30072 shows activity against superbugs expressing the NDM-1 resistance factor
- Rib-X Pharmaceuticals Presents Data at ECCMID for Three Novel Classes of Broad-spectrum Antibiotic Compounds From the RX-04 Development Program
- Acceleron Pharma Presents Anabolic Bone Effects of ACE-661 at International Scientific Meeting
- Rib-X Pharmaceuticals Presents Data at ECCMID Demonstrating Potent In Vitro Activity of Radezolid and Delafloxacin Against Resistant Strains of Gram-positive Bacteria
- Diamyd Medical: Diamyd Reports Initial Results from European Phase III Trial in Patients Newly Diagnosed with Type 1 Diabetes
- Chelsea Therapeutics Announces Approval to Open Enrollment Into 3.0 mg Arms of CH-4051 Phase II Trial in Rheumatoid Arthritis
- Salix Pharmaceuticals Outlines Data Presentations at Digestive Disease Week 2011
- Phase 2b Data Show Treatment With Stelara Induced and Maintained Clinical Response in Patients With Moderate to Severe Crohn's Disease
- Immusan Reports Positive Results from Nexvax2 Phase 1 Study in Celiac Disease
- Inovio Pharmaceuticals Reports Long-Term Immune Responses from Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
- Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial
- Rhythm's RM-131 Restores GI Function as a Potent Ghrelin Prokinetic
- Forest and Almirall to Present Data from Phase III Studies of Aclidinium Bromide in Chronic Obstructive Pulmonary Disease (COPD)
- Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID Phase 3 Data
May 10, 2011
- Durata Announces Antibiotic Surveillance Results for Dalbavancin Presented at ECCMID Meeting
- New analysis of Resolor data demonstrates acceleration of colonic transit time associated with improved bowel function in women with chronic constipation
- Top-line Results of the Pivotal Phase 3 Clinical Trial of TAK-085 in Japan for Treatment of Hypertriglyceridemia
- New Phase 3 Study Results Show Remicade Is Effective in the Treatment of Pediatric Patients With Moderate to Severe Ulcerative Colitis
- Abbott's Humira (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study
- Data Presented at ECCMID Illustrate Risk Factors for Negative Outcomes in C. Difficile Patients
- GATTEX (teduglutide) Shown to Reduce Parenteral Support Volume in Patients with Adult Short Bowel Syndrome
- Progesterone and TBI: Encore Therapeutics Inc. Completes Novel Commercially Enabling Progesterone Formulation for TBI
- Cimzia (certolizumab pegol) Data Showed Rapid Improvement in Signs and Symptoms Predicted Better Long-Term Outcomes in Rheumatoid Arthritis Patients
- Mayo Clinic Researchers Find New Treatment for Constipation
- Cimzia (certolizumab pegol) Data Showed Broad and Rapid Relief From Burden of Symptoms In Rheumatoid Arthritis Patients
- Kowa Announces the Efficacy and Safety of a Novel Rho Kinase Inhibitor (K-115) in the Treatment of Glaucoma in ARVO 2011
- Alkermes Presents Phase 2 Data of ALKS 37 in Late-Breaking Oral Session at Digestive Disease Week Meeting
- Meritage Pharma Reports Positive Phase 2b Data for Oral Budesonide Suspension in Pediatric Patients with Eosinophilic Esophagitis
- Short Term Use of Painkillers Could Be Dangerous to Heart Patients
May 11, 2011
- Results of a Phase II Clinical Trial for Ranirestat - Therapeutic Agent for Diabetic Complications
- Dainippon Sumitomo Pharma Announces Pan-Asia Study Results for Lurasidone, An Atypical Antipsychotic Agent, in the Treatment of Schizophrenia
- Can-Fite Announces a Promising Interim Analysis Data of Its Phase I/II Liver Cancer Study with the CF102 Drug
May 12, 2011
- Atox Bio Announces Successful Completion of Phase 1 for AB103, a Novel Immunomodulator Being Developed for Severe Bacterial Infections and Sepsis.
- PolyMedix Presents Clinical and Pre-Clinical Data on PMX-30063 Defensin-Mimetic Antibiotic at ECCMID 2011 Meeting
- Scientists for the First Time Regenerate Sections of Retinas and Increase Visual Function With Stem Cells Derived From Skin
- Initiation of Antiretroviral Treatment Protects Uninfected Sexual Partners from HIV Infection (HPTN Study 052)
May 13, 2011
- Long-Term Data on Avanafil to be Presented at the American Urological Association Annual Meeting
- MedImmune To Present Eight Abstracts on Projects Regarding Thoracic and Respiratory Issues at the Annual American Thoracic Society International Conference
- Theron Pharmaceuticals to Present at the American Thoracic Society Conference on May 15th, 2011 in Denver, Colorado
- Sickle Cell Anemia Drug Shown Safe and Effective for Infants and Toddlers, Improving Treatment Options
- DIFICID Data Presented at American Geriatric Society Annual Meeting Demonstrates that Advancing Age is Associated with Progressive Deterioration of Treatment Outcomes in Patients with Clostridium difficile Infection
- DIFICID Data Presented at American Geriatric Society Annual Meeting Demonstrates that Advancing Age is Associated with Progressive Deterioration of Treatment Outcomes in Patients with Clostridium difficile Infection
- CMX001 Shows Antiviral Activity in Immunocompromised Transplant Patients With Severe Adenovirus Infection
- Dificid Data Presented at American Geriatric Society Annual Meeting Demonstrates that Advancing Age is Associated with Progressive Deterioration of Treatment Outcomes in Patients with Clostridium difficile Infection
- Micell Technologies Reports Preclinical Data for MiStent(TM) Drug-Eluting Coronary Stent to be Presented at EuroPCR
May 16, 2011
- Pfizer To Present New Research From Fifteen Compounds Highlighting Multiple Approaches To Targeting Cancer At 2011 ASCO Annual Meeting
- InterMune Announces Presentation of Positive Pirfenidone Data at the International Conference of the American Thoracic Society (ATS)
- CEO of ARCA biopharma to Present Gencaro Development Programs at the European Society of Cardiology's Heart Failure Congress 2011
- Novartis Studies Show Onbrez Breezhaler Plus Tiotropium Is More Effective Than Tiotropium Alone in Treatment of COPD
- Thallion's Phase II Shigatec Trial Proceeds to High Dose Cohort
- Long-Term Study Demonstrates Safety and Efficacy of Symbicort in African American Patients With Asthma
- No Increase in Severe Cardiovascular Events for Children, Adolescents Taking ADHD Medications
- Otsuka Pharmaceutical Co., Ltd. Announces Results from a Phase 2 Study of Investigational Product OPC-34712 as Adjunctive Therapy in Adults with Major Depressive Disorder
- H. Lundbeck A/S (DK) - Data from four clinical phase III studies of Lu AA21004 presented for the first time at the 2011 Annual Meeting of the American Psychiatric Association (APA)
- Pediatrics Study Finds Children Taking ADHD Medications Did Not Suffer More Serious Heart Problems or Cardiovascular-related Death
- Exploratory Efficacy Analysis Conducted for Long-Term Extension Study in Patients With Prostate Cancer Treated With FIRMAGON or Crossed Over to FIRMAGON From Leuprolide
- Novel ACR Hybrid Score in Rheumatoid Arthritis Applied for the First Time to Data from the RAPID 1 Study with Cimzia (certolizumab pegol)
- Stopping HIV Transmission with a Molecular Barrier
- MedImmune To Present Eight Abstracts on Projects Regarding Thoracic and Respiratory Issues at the Annual American Thoracic Society International Conference
May 17, 2011
- Data Published in Journal of Clinical Oncology Highlights Significant Activity of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia
- InterMune Announces Presentation of Positive Pirfenidone Data at the International Conference of the American Thoracic Society (ATS)
- Teva and CureTech Announce Positive Phase II Data from CT-011, an Investigational Antibody in Diffuse Large B Cell Lymphoma
- Lantheus Announces New Cardiac PET Diagnostic Data at ICNC
- Unigene Announces Presentations on Proprietary Recombinant Production and Oral Peptide Drug Delivery Technology at Upcoming 2011 TIDES Summit
- Genta Announces Clinical Presentations on Lead Compounds, Tesetaxel and Genasense, at 2011 Annual ASCO Meeting
- Ajinomoto AminoScience to Speak and Exhibit at TIDES 2011 in Boston
- New Survey Reveals Most Americans Unaware of Gout Risk Factors, in the Dark About Connection to Diabetes, Kidney Disease, and Cardiac Problems
- Positive Results from Long-Term Phase 3 Study of Avanafil Featured at American Urological Association Annual Meeting
- Denosumab May Prolong Metastasis-Free Survival in Men with High-Risk Prostate Cancer
- Watson Pharmaceuticals Announces New Research Showing Rapalfo (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
- Presentations by Vical and Collaborators at CMV/BetaHerpesvirus Workshop
May 18, 2011
- Pfizer's Anti-TNF-Alpha Nanobody (ATN-103) Successfully Completes A Phase Ii Study And Demonstrates Clinical Proof-Of-Concept (Poc) In Patients With RA
- Amgen: Data Shows Xgeva Prevents Cancer from Spreading in Advanced Prostate Cancer Patients
- Firmagon (degarelix for injection) Extension Study Analysis Presented at AUA 2011
- Plexxikon Announces Data Presentations of Oncology Pipeline, Including Phase 3 Vemurafenib Data, at ASCO 2011 Annual Meeting
- Seaside Therapeutics Publishes Review of Advances in the Treatment of Fragile X Syndrome in American Chemical Society Chemical Neuroscience
- Prenatal Use of Newer Antiepileptic Drugs Not Associated With Increased Risk of Major Birth Defects
- BIOTRONIK Announces Positive 6-Month Results for DREAMS, the Pioneering Drug-Eluting Absorbable Metal Scaffold
- Pearl Therapeutics' Phase 2b Results Show a 50% Improvement in Lung Function with PT003 Compared to Spiriva and Foradil in Patients with COPD
- ARX-01 and ARX-03 Clinical Results Presented at the 30th Annual Scientific Meeting of the American Pain Society
- BIOTRONIK Announces Positive 6-Month Results for DREAMS, the Pioneering Drug-Eluting Absorbable Metal Scaffold
- Industry's First Hybrid Drug-Eluting Stent from BIOTRONIK Demonstrates Safety and Efficacy in First-in-Man Clinical Experience
- Randomized Study Combining L-Methylfolate With Antidepressant Shows Significant Boost in Patient Response
May 19, 2011
- EntreMed ENMD-2076 Phase 2 Data to Be Presented at ASCO Annual Meeting
- RXi Pharmaceuticals Presents Updated NeuVax (E75) Data At ASCO
- PolyMedix PMX-30063 Defensin-Mimetic Antibiotic Compound Shows Promising Activity for Oral Mucositis
- Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting
- Urocidin Phase III Clinical Trial Results Presented at AUA Conference in Washington, D.C.
- Vildagliptin is significantly more effective in the management of Type 2 diabetes in South Asian Muslims fasting during Ramadan than the most commonly prescribed treatment
- Pharmacyclics Announces Oral Presentations and Clinical Update at Upcoming Medical Meetings
- Omeros Announces Clinical Development Programs for OMS103HP and OMS302
- Seattle Genetics to Present Brentuximab Vedotin and SGN-75 Clinical Data at the American Society of Clinical Oncology Annual Meeting
- AMRI to Present Obesity Compound Phase I Clinical Results
- YM BioSciences Reports Updated 12-Week Phase I/II Results for its JAK1/JAK2 Inhibitor CYT387
- Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study
- VBL Therapeutics Presents Preclinical Data for VB-111 at the 14th Annual ASGCT Meeting
- Nexavar Data to Be Presented at American Society of Clinical Oncology Annual Meeting
- Teva and OncoGenex to Present Data on Custirsen in Prostate Cancer at the 2011 ASCO Annual Meeting
- Onyx Pharmaceuticals Announces Data Presentations of Carfilzomib and ONX 0912 at 47th American Society of Clinical Oncology Annual Meeting
- CDG Therapeutics, Inc. Selected to Deliver Oral Presentation of ?First in Class, First in Human? Phase I Trial Results at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO)
- Peregrine Reports Promising Interim Survival Data From Phase II Cotara Recurrent GBM Trial
- Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting
- Study Shows Sutro Biopharma's Biochemical Protein Synthesis Technology Enables Rapid Production and Scale-Up of Biopharmaceuticals
- Study Determined Best Dose and Showed 55 Percent Response Rate With Lilly Anti-BAFF Monoclonal Antibody in Previously-Treated Multiple Myeloma Patients
- Heart Drugs Ineffective in Treating Pulmonary Arterial Hypertension
- Animal Results May Pave Way to Treating Rare Mitochondrial Diseases in Children
- Lilly Presents Data on Cixutumumab in Five Subtypes of Sarcoma
- Study Characterizes Extractability Properties of Once-Daily Extended-Release Hydromorphone
May 20, 2011
- Salix Pharmaceuticals Reviews Data Presentations at American Pain Society Annual Meeting
- Medtronic Resolute Drug-Eluting Stent Exhibits Strong Safety Profile in Broad Spectrum of Patients
- Multiple Presentations Featuring QNEXA Data to be Presented at the European Congress on Obesity
- Medivir Announces Positive 48-week Interim Data from TMC435 Hepatitis C Phase 2b ASPIRE Study in Treatment-Experienced Genotype-1 Patients
- Progenics Announces Results of Methylnaltrexone Phase 3 Safety Study in Chronic, Non-Malignant Pain Patients
- Viagra Could Reduce Multiple Sclerosis Symptoms
- Use of naltrexone Reduces Inflammation in Crohn's Patients
- Onyx Pharmaceuticals Announces Updated Pivotal Carfilzomib Phase 2B Data
- Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer
- Study Characterizes Extractability Properties of once-Daily Extended-Release Hydromorphone
May 21, 2011
May 23, 2011
- Pacira Pharmaceuticals, Inc. Announces EXPAREL Data Presentations at the International Anesthesia Research Society 2011 Annual Meeting
- Santarus Announces Presentation of RHUCIN Clinical Data at 7th C1 Inhibitor Deficiency Workshop
- Micromet to Report Blinatumomab Data at June Medical Conferences
- Spectrum Pharmaceuticals Announces ZEVALIN and Belinostat Abstracts to Be Presented at the American Society of Clinical Oncology Annual Meeting
- PROLOR To Present Long-Acting Obesity and Multiple Sclerosis Drug Candidates at Leading Neuropeptide Conference
- Researchers to Present Nine Studies on Soliris (eculizumab) in Patients with PNH and aHUS at EHA Congress
- Vancomycin Continues to Dominate MRSA Treatment with up to 76 Percent of Surveyed Infectious Disease Specialists Indicating That They Use the Agent as First-Line Treatment for a Range of MRSA Infections
- Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights
- Led by Advances in Chemical Synthesis, Scripps Research Scientists Discover that a Rare Natural Product Has Potent Pain-Killing Properties
May 24, 2011
- Actelion's novel CRTH2 antagonist meets primary endpoint in Phase II study in patients with seasonal allergic rhinitis
- Phase 3 Trial of Genasense in Advanced Melanoma Does Not Show Significant Increase in Overall Survival
- Biotie announces topline data from an exploratory phase 2a study with SYN118 in Parkinson's disease
- Oxford BioMedica Announces Presentation of New Clinical Data from ProSavin Phase I/II Study in Parkinson's Disease
- New data support efficacy of Ruconest across all HAE attack locations
- New Clinical Trial Data Support the Use of Levemir in Children Aged Two to Five Years
- KemPharm, Inc. Announces Positive Results from Phase 1 Trial of KP201 for Pain
- ImmunoCellular Therapeutics to Present New Data from Phase I Study of ICT-107 in Glioblastoma Multiforme at ASCO 2011
- Celladon Corporation Announces MYDICAR Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Reduction in Clinical Events in Patients for 18 Months Compared with Placebo
- Study Finds Long-Term Treatment with TRIBENZOR was Effective and Well-Tolerated Regardless of Age, Race, or Diabetes Status
- Relypsa Announces Presentation of Positive Phase 2 Results for RLY5016 at American Society of Hypertension Meeting
- Santarus Announces Presentation of RHUCIN Clinical Data at 7th C1 Inhibitor Deficiency Workshop
May 25, 2011
- PolyMedix Presents Antimicrobial Compound Data at Two Prestigious Scientific Meetings
- VBL Therapeutics To Present Updated Clinical Results for VB-111 at 2011 ASCO Annual Meeting
- Aileron Therapeutics to Present at Several Upcoming Peptide Drug Discovery Conferences
- New Four Year Stelara Data Show Consistent Safety Profile Over Time in Patients With Moderate to Severe Plaque Psoriasis
- Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis
- Novartis Data Shows ACZ885 for Severe Gouty Arthritis Provided Better Pain Relief and Reduced Risk of New Attacks By Up to 68% Vs. Steroid
- Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel (etanercept) for Patients with Chronic Inflammatory Conditions
- Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD)
- Amsterdam Molecular Therapeutics Research Demonstrates AAV Delivery May Be Key Success Factor for Therapeutic Promise of RNAi
- Nearly 1 in 5 Young Adults Has High Blood Pressure, Study Shows
- Dangerous Side Effect of Common Drug Combination Discovered By Stanford Data Mining
- Pieris Announces Preclinical In Vitro and In Vivo Data for its Anticalin PRS-080 Hepcidin Antagonist Drug Program
- Basilea reports positive results from first clinical phase I study with its novel antibiotic BAL30072
- Ampio Pharmaceuticals, Inc. Completes Evaluation of Data From Phase III Clinical Trials of Zertane(TM) for Treatment of the Most Common Male Sexual Dysfunction, Premature Ejaculation
- Data From a Phase 1 Clinical Trial of Exelixis' Cabozantinib Published in the Journal of Clinical Oncology
- Sangamo BioSciences and Collaborators Present Data Showcasing Broad Applications of ZFP Therapeutics
May 26, 2011
- BioCryst Presents New Analyses of BCX4208 Phase 2 Studies in Patients with Gout at the Annual European Congress of Rheumatology
- ImmunoGen, Inc. Announces Clinical Presentations at the ASCO 2011 Annual Meeting
- Zytiga Phase 3 Study Results re Metastatic Castration-Resistant Prostate Cancer
- Pfizer Announces Detailed Results Of ORAL Sync Showing Investigational Compound Tofacitinib Reduces Signs And Symptoms And Improves Physical Function In Patients With Moderate-To-Severe Active Rheumatoid Arthritis, With Results Seen As Early As Two Weeks
- Successful Proof of Concept for topical antimicrobial drug Lytixar: Completion of two Phase I/IIa clinical studies
- Synta Announces Publication of Results Showing Ganetespib (STA-9090) Exhibits Potent Activity in Models of Cancer with Activated JAK/STAT Signaling
- Dynavax Completes Phase 3 Study of Heplisav
- CEL-SCI Corporation Study Shows LEAPS Dendritic Cell Therapy to Be Effective in Treating H1N1 Virus
- Neurologix Presents One-Year Follow-Up Data From Phase 2 Study of NLX-P101 in Parkinson's Disease at International Neuromodulation Society 10th World Congress
- Pivotal Phase 3 Study Published in The New England Journal of Medicine (NEJM) Finds Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer is Significantly Improved with Zytiga (abiraterone acetate)
- Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
- Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals' Lorcaserin Achieved Statistically Significant Weight Loss
- US Oncology Research Affiliated Physicians to Present at 2011 ASCO Annual Meeting
- Abbott Statement on Interim Study Results of AIM-HIGH
- Abbott Statement on Interim Study Results of AIM-HIGH
- NIH Stops Clinical Trial on Combination Cholesterol Treatment
- Tragara Pharmaceuticals' Apricoxib Reverses EMT, a Key Process for Cancer Progression and Metastasis
May 27, 2011
- EULAR 2011 - Vidofludimus Superior to Cyclophosphamide and MMF in an Experimental Systemic Lupus Erythematosus Model
- Abiraterone Acetate Significantly Improves Overall Survival of Patients with Post-Chemotherapy Metastatic Castration-Resistant Prostate Cancer
- RoActemra Could Change the Current Standard of Treatment for People With RA
- Arthritis Patients Taking Newer Treatments Do Not Have An Overall Increased Cancer Risk
- Omega-3 May Cut Risk of Artery Disease, Heart Attacks for Patients with Stents
- New Data for Cimzia (Certolizumab Pegol) Showed a Rapid Clinical Response Across a Broad Population of Rheumatoid Arthritis (RA) Patients
- SciFluor Life Sciences' Founders Author Review Article in Nature on Advances to Overcome Challenges Associated with Fluorination
- Millennium and Seattle Genetics Announce Brentuximab Vedotin (SGN-35) Presentations at 16th Congress of the European Hematology Association
